NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free VCNX Stock Alerts $8.20 +0.15 (+1.86%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$8.06▼$8.7350-Day Range$7.56▼$12.2552-Week Range$7.16▼$100.80Volume2,915 shsAverage Volume12,295 shsMarket Capitalization$7.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vaccinex alerts: Email Address Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About Vaccinex Stock (NASDAQ:VCNX)Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.Read More VCNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCNX Stock News HeadlinesMarch 6, 2024 | investing.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 2, 2024 | morningstar.comVaccinex Inc VCNXMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 21, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyFebruary 21, 2024 | markets.businessinsider.comVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 15, 2024 | markets.businessinsider.comVaccinex Announces 1-For-14 Reverse Stock SplitMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 15, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Trading LowerFebruary 15, 2024 | globenewswire.comVaccinex, Inc. Announces Reverse Stock SplitFebruary 12, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex IncFebruary 8, 2024 | msn.comVaccinex Inc Secures $3.7M in Private Placement DealFebruary 7, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Popping OffFebruary 7, 2024 | markets.businessinsider.comVaccinex Announces Pricing of $3.7 Million PIPE FinancingDecember 4, 2023 | finance.yahoo.comNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingOctober 26, 2023 | finance.yahoo.comVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOctober 6, 2023 | markets.businessinsider.comWhy Is Vaccinex (VCNX) Stock Up 26% Today?September 29, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 29, 2023 | marketwatch.comVaccinex Shares Slide Premarket After Stock OfferingSeptember 29, 2023 | finance.yahoo.comVaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 28, 2023 | stockhouse.comVaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 28, 2023 | finance.yahoo.comVaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 27, 2023 | finance.yahoo.comVaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® ApplicationSeptember 26, 2023 | benzinga.comVaccinex Recent Insider ActivitySee More Headlines Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/18/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VCNX CUSIPN/A CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($84.5602) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,820,000.00 Net MarginsN/A Pretax Margin-2,768.80% Return on Equity-2,667.31% Return on Assets-475.55% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual Sales$280,000.00 Price / Sales26.06 Cash FlowN/A Price / Cash FlowN/A Book Value$21.86 per share Price / Book0.38Miscellaneous Outstanding Shares890,000Free Float434,000Market Cap$7.30 million OptionableOptionable Beta0.76 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Maurice Zauderer Ph.D. (Age 78)Co-Founder, CEO, President & Director Comp: $400.7kDr. Elizabeth E. Evans Ph.D. (Age 52)COO and Senior VP of Discovery & Translational Medicine Comp: $255.46kDr. Ernest S. Smith Ph.D. (Age 52)Senior VP of Research & Chief Scientific Officer Comp: $284.02kMr. Scott E. Royer C.F.A. (Age 50)M.B.A., Chief Financial Officer Comp: $242.15kDr. John E. Leonard Ph.D. (Age 77)Senior Vice President of Development Key CompetitorsGraybug VisionNASDAQ:GRAYSoligenixNASDAQ:SNGXPasithea TherapeuticsNASDAQ:KTTAGT BiopharmaNASDAQ:GTBPCadrenal TherapeuticsNASDAQ:CVKDView All CompetitorsInsiders & InstitutionsAIGH Capital Management LLCSold 273,112 shares on 2/12/2024Ownership: 6.542%Worth Venture Partners LLCSold 63,480 shares on 2/9/2024Ownership: 5.237%Simplex Trading LLCSold 600 shares on 2/2/2024Ownership: 0.000%Strydonck Gerald E. VanSold 224 sharesTotal: $2,257.92 ($10.08/share)Albert FriedbergBought 214,285 shares on 10/3/2023Total: $3.00 M ($14.00/share)View All Insider TransactionsView All Institutional Transactions VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed in 2024? Vaccinex's stock was trading at $9.3072 at the beginning of 2024. Since then, VCNX shares have decreased by 11.9% and is now trading at $8.20. View the best growth stocks for 2024 here. Are investors shorting Vaccinex? Vaccinex saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 14,800 shares, an increase of 21.3% from the February 14th total of 12,200 shares. Based on an average daily trading volume, of 10,700 shares, the days-to-cover ratio is currently 1.4 days. Currently, 2.5% of the shares of the company are short sold. View Vaccinex's Short Interest. When is Vaccinex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our VCNX earnings forecast. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, topping analysts' consensus estimates of ($60.90) by $25.20. The business had revenue of $0.05 million for the quarter. When did Vaccinex's stock split? Vaccinex shares reverse split on the morning of Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX). When did Vaccinex IPO? (VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager. Who are Vaccinex's major shareholders? Vaccinex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (6.54%), Worth Venture Partners LLC (5.24%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van. View institutional ownership trends. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCNX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.